NCT01884675 - Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Hypertension

Interventions

DRUG

Ambrisentan 5 mg

White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.

DRUG

Placebo

White, film-coated, ambrisentan-matching placebo tablet for single oral dose

Trial Locations (51)

1090

GSK Investigational Site, Vienna

28041

GSK Investigational Site, Madrid

28222

GSK Investigational Site, Majadahonda (Madrid)

30625

GSK Investigational Site, Hanover

41013

GSK Investigational Site, Seville

64718

GSK Investigational Site, Monterrey NL

66421

GSK Investigational Site, Homburg

69126

GSK Investigational Site, Heidelberg

70300

GSK Investigational Site, Zrifin

78360

GSK Investigational Site, Ashkelon

93053

GSK Investigational Site, Regensburg

97074

GSK Investigational Site, Würzburg

100020

GSK Investigational Site, Beijing

100037

GSK Investigational Site, Beijing

100038

GSK Investigational Site, Beijing

200433

GSK Investigational Site, Shanghai

430022

GSK Investigational Site, Wuhan

630055

GSK Investigational Site, Novosibirsk

634012

GSK Investigational Site, Tomsk

650002

GSK Investigational Site, Kemerovo

710061

GSK Investigational Site, Xi'an

02118

GSK Investigational Site, Boston

75390-8550

GSK Investigational Site, Dallas

W3400AMZ

GSK Investigational Site, Corrientes

S2000ODA

GSK Investigational Site, Rosario

Unknown

GSK Investigational Site, Santa Fe

GSK Investigational Site, Riyadh

C1181ACH

GSK Investigational Site, Buenos Aires

A-8036

GSK Investigational Site, Graz

A-6020

GSK Investigational Site, Innsbruck

T6G 2G3

GSK Investigational Site, Edmonton

N6A 5W9

GSK Investigational Site, London

128 08

GSK Investigational Site, Prague

01307

GSK Investigational Site, Dresden

04103

GSK Investigational Site, Leipzig

466-8560

GSK Investigational Site, Aichi

812-8582

GSK Investigational Site, Fukuoka

060-8648

GSK Investigational Site, Hokkaido

650-0017

GSK Investigational Site, Hyōgo

980-8574

GSK Investigational Site, Miyagi

329-0498

GSK Investigational Site, Tochigi

113-8655

GSK Investigational Site, Tokyo

181-8611

GSK Investigational Site, Tokyo

1081 HV

GSK Investigational Site, Amsterdam

110-744

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

08036

GSK Investigational Site, Barcelona

CB23 3RE

GSK Investigational Site, Cambridge

G81 4DY

GSK Investigational Site, Clydebank

NW3 2QH

GSK Investigational Site, London